Sinopharm Group

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Not to be confused with Sinopharm, the short name of the parent company China National Pharmaceutical Group.
Sinopharm Group
public
Traded as
unlisted(A share)
SEHK: 1099(H share)
ISINCNE100000FN7
IndustryPharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
FounderChina National Pharmaceutical Group
HeadquartersSinopharm Plaza,
Shanghai
,
China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
Revenue CN¥227.069 billion (2015)
CN¥9.169 billion (2015)
CN¥3.761 billion (2015)
Total assets CN¥138.267 billion (2015)
Total equity CN¥30.052 billion (2015)
OwnerSinopharm Industrial Investment (56.79%)
ParentSinopharm Industrial Investment
SubsidiariesSinopharm CNMC
Websitewww.sinopharmgroup.com.cn 
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1]
Sinopharm Group Co., Ltd.
Simplified Chinese国药控股股份有限公司
Traditional Chinese國藥控股股份有限公司
Literal meaningSinopharm Holding Joint-Stock Limited Company
Sinopharm Group
Simplified Chinese国药控股
Traditional Chinese國藥控股
Literal meaningSinopharm Holding
Second alternative Chinese name
Simplified Chinese国控股份有限公司
Traditional Chinese國控股份有限公司

Sinopharm Group researches and develops, manufactures, distributes, and markets medicine and other healthcare products.[2] Sinopharm Group manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China.

Its H shares were listed on the Hong Kong Stock Exchange in 2009,[3] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[4]

See also

References
  1. "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016.
  2. "Sinopharm Group Co. Ltd.: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2017-07-27.
  3. China's Sinopharm gets OK for $1 bln HK IPO
  4. https://www.forbes.com/companies/sinopharm-group/
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.